BR112021022363A2 - Composições e métodos para fabricação de células t - Google Patents
Composições e métodos para fabricação de células tInfo
- Publication number
- BR112021022363A2 BR112021022363A2 BR112021022363A BR112021022363A BR112021022363A2 BR 112021022363 A2 BR112021022363 A2 BR 112021022363A2 BR 112021022363 A BR112021022363 A BR 112021022363A BR 112021022363 A BR112021022363 A BR 112021022363A BR 112021022363 A2 BR112021022363 A2 BR 112021022363A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- manufacturing
- compositions
- methods
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Casting Or Compression Moulding Of Plastics Or The Like (AREA)
- Moulding By Coating Moulds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845251P | 2019-05-08 | 2019-05-08 | |
| PCT/US2020/031898 WO2020227546A1 (en) | 2019-05-08 | 2020-05-07 | T cell manufacturing compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022363A2 true BR112021022363A2 (pt) | 2022-03-22 |
Family
ID=73051205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022363A BR112021022363A2 (pt) | 2019-05-08 | 2020-05-07 | Composições e métodos para fabricação de células t |
Country Status (15)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2812431B1 (en) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| JP2023539056A (ja) * | 2020-08-13 | 2023-09-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
| US11948694B2 (en) * | 2021-05-12 | 2024-04-02 | Merative Us L.P. | Controlling compartmental flows in epidemiological modeling based on mobility data |
| US12062456B2 (en) | 2021-05-27 | 2024-08-13 | Merative Us L.P. | Hypothetical scenario evaluation in infectious disease dynamics based on similar regions |
| IL312121A (en) * | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| JP2026500232A (ja) * | 2022-12-09 | 2026-01-06 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
| KR20240112760A (ko) * | 2023-01-12 | 2024-07-19 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
| WO2025245488A2 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| IL106610A0 (en) | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
| SG49008A1 (en) | 1993-03-05 | 1998-05-18 | Cytel Corp | Hla-a2.1 binding peptides and their uses |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| EP1545610A4 (en) | 2002-09-06 | 2006-11-08 | Mannkind Corp | EPITOPE SEQUENCES |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2006015497A1 (en) | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors |
| US20060286089A1 (en) * | 2005-04-08 | 2006-12-21 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| US9809797B2 (en) * | 2007-10-03 | 2017-11-07 | National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression |
| WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| EP2490713A2 (en) | 2009-10-23 | 2012-08-29 | MannKind Corporation | Cancer immunotherapy and method of treatment |
| US9115402B2 (en) | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| SG11201404570WA (en) * | 2012-02-10 | 2014-11-27 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| US20150104441A1 (en) | 2013-10-11 | 2015-04-16 | Oslo Universitetssykehus Hf | Identification of disease-driving antigens |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US10627411B2 (en) | 2014-03-27 | 2020-04-21 | British Columbia Cancer Agency Branch | T-cell epitope identification |
| IL292038B2 (en) | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| JP6661544B2 (ja) | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
| CN103923880B (zh) | 2014-05-08 | 2016-03-30 | 成都百赛泰科生物科技有限公司 | 一种高效增殖、靶向杀伤肿瘤的ctl制备方法 |
| SG11201702191YA (en) | 2014-09-17 | 2017-04-27 | Univ Johns Hopkins | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| CA3172801A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| DE102015214780A1 (de) * | 2015-08-03 | 2017-02-09 | Continental Automotive Gmbh | Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems |
| EP3335725B1 (en) | 2015-08-10 | 2024-02-28 | Toray Industries, Inc. | Pds5a epitopes as immunity inducers |
| KR20180043800A (ko) | 2015-09-09 | 2018-04-30 | 이뮨 디자인 코포레이션 | Ny-eso-1 특이적 tcrs 및 그의 사용 방법 |
| AU2016319126A1 (en) | 2015-09-10 | 2018-04-19 | Affigen, Inc. | Sequencing-directed selection of tumor theranostics |
| WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
| SG11201808196UA (en) | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| WO2017177337A1 (en) | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| JP7054397B2 (ja) | 2016-06-27 | 2022-04-13 | ジュノー セラピューティクス インコーポレイテッド | Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用 |
| AU2017305396A1 (en) | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| CN110809716B (zh) | 2017-02-12 | 2023-07-07 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| CA3124457A1 (en) | 2018-12-21 | 2020-06-25 | Biontech Us Inc. | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
| US20220282217A1 (en) | 2019-03-30 | 2022-09-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| US20230398218A1 (en) | 2020-08-13 | 2023-12-14 | Biontech Us Inc. | Ras neoantigens and uses thereof |
| JP2023539056A (ja) | 2020-08-13 | 2023-09-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
| IL312121A (en) | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| JP2026500232A (ja) | 2022-12-09 | 2026-01-06 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
-
2020
- 2020-05-05 TW TW111130596A patent/TWI867324B/zh active
- 2020-05-05 TW TW109114957A patent/TWI777160B/zh active
- 2020-05-05 AR ARP200101269A patent/AR118859A1/es unknown
- 2020-05-07 MX MX2021013608A patent/MX2021013608A/es unknown
- 2020-05-07 CA CA3137037A patent/CA3137037A1/en active Pending
- 2020-05-07 KR KR1020247036158A patent/KR20240161214A/ko active Pending
- 2020-05-07 PH PH1/2021/552829A patent/PH12021552829A1/en unknown
- 2020-05-07 AU AU2020268397A patent/AU2020268397A1/en active Pending
- 2020-05-07 WO PCT/US2020/031898 patent/WO2020227546A1/en not_active Ceased
- 2020-05-07 SG SG11202112346WA patent/SG11202112346WA/en unknown
- 2020-05-07 US US17/609,705 patent/US12653887B2/en active Active
- 2020-05-07 BR BR112021022363A patent/BR112021022363A2/pt unknown
- 2020-05-07 JP JP2021566008A patent/JP7582971B2/ja active Active
- 2020-05-07 CN CN202511339181.5A patent/CN121086984A/zh active Pending
- 2020-05-07 CN CN202080050310.8A patent/CN114096261B/zh active Active
- 2020-05-07 EP EP20801696.4A patent/EP3965784A4/en active Pending
- 2020-05-07 KR KR1020217040167A patent/KR102756321B1/ko active Active
-
2021
- 2021-11-07 IL IL287874A patent/IL287874A/en unknown
-
2024
- 2024-01-29 JP JP2024011014A patent/JP7855622B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220044242A (ko) | 2022-04-07 |
| MX2021013608A (es) | 2022-01-31 |
| SG11202112346WA (en) | 2021-12-30 |
| WO2020227546A1 (en) | 2020-11-12 |
| CN114096261B (zh) | 2025-09-26 |
| CN114096261A (zh) | 2022-02-25 |
| JP2024038503A (ja) | 2024-03-19 |
| TWI777160B (zh) | 2022-09-11 |
| JP7855622B2 (ja) | 2026-05-08 |
| JP7582971B2 (ja) | 2024-11-13 |
| KR102756321B1 (ko) | 2025-01-16 |
| US12653887B2 (en) | 2026-06-16 |
| TW202108761A (zh) | 2021-03-01 |
| IL287874A (en) | 2022-01-01 |
| EP3965784A4 (en) | 2023-06-21 |
| JP2022531474A (ja) | 2022-07-06 |
| KR20240161214A (ko) | 2024-11-12 |
| TW202248419A (zh) | 2022-12-16 |
| CN121086984A (zh) | 2025-12-09 |
| AU2020268397A1 (en) | 2022-01-06 |
| PH12021552829A1 (en) | 2023-01-16 |
| US20220280621A1 (en) | 2022-09-08 |
| TWI867324B (zh) | 2024-12-21 |
| CA3137037A1 (en) | 2020-11-12 |
| AR118859A1 (es) | 2021-11-03 |
| EP3965784A1 (en) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013608A (es) | Composiciones y métodos de fabricacion de celulas t. | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| BR112023002733A2 (pt) | Composições e métodos de fabricação de células t | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
| BR112022005423A2 (pt) | Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap) | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| MX2020009773A (es) | Terapia de combinacion. | |
| BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
| MX2024011262A (es) | Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa. | |
| BR112018007671A2 (pt) | terapia de combinação para tratamento de malignidades | |
| DOP2007000015A (es) | Usos terapéuticos de inhibidores de rtp801 | |
| MX2019012465A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25. | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| BR112021021787A2 (pt) | Terapias de combinação | |
| AR109707A1 (es) | Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre | |
| MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| MX2015006268A (es) | Diferenciacion de las celulas de fibroblastos humanos. | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| MX2021015403A (es) | Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario. | |
| MX2023011790A (es) | Terapias combinadas para tratar el cancer. | |
| BR112018067967A2 (pt) | tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante | |
| ZA202105301B (en) | Targeted delivery of therapeutic molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |